Decibel Cannabis reported higher quarterly revenue November 19, with international sales offsetting a weaker Canadian recreational business. Net revenue reached C$35.1 million for the three months ended September 30, up 7% from a year earlier. The contrast between its two markets is the central story: international sales rose 44% to C$12.1 million, while domestic sales fell 6% to C$23.0 million.
The Canadian cannabis company also issued its first quarterly shareholder letter, pairing results with management’s account of where the business needs work. Together, the documents describe an exporter gaining momentum while trying to rebuild performance at home. They are company disclosures, not independent confirmation that its strategy will deliver future growth.
What Decibel’s third-quarter results show
In its corrected November 19 release, Decibel reported C$7.4 million in adjusted EBITDA and C$1.1 million in free cash flow. Gross margin before fair-value adjustments was 52%, compared with 47% a year earlier. All dollar figures here are Canadian dollars.
Management reaffirmed full-year net-revenue guidance of C$132 million to C$137 million and adjusted EBITDA of C$28 million to C$32 million. Those ranges are forecasts, not completed annual results. The company identifies adjusted EBITDA and free cash flow as non-GAAP measures, which means they should be read alongside its financial statements rather than treated as substitutes for conventional earnings or operating cash flow.
The figures answer different questions. Revenue measures sales; a margin describes the relationship between revenue and specified costs; cash flow concerns money moving through the business. Growth in one does not establish equivalent progress in all three. That is particularly useful context when international expansion is carrying more of the sales total.
Management’s letter puts Canada in focus
The shareholder letter, signed by executive chairman Shawn Dym and chief executive Benjamin Sze, acknowledges that Canadian execution needs improvement. Management says it changed commercial leadership during the quarter and intends to address gaps in flower and standard pre-rolls under General Admission.
The letter describes international business as roughly 35% of quarterly revenue, compared with about 4% in 2024. It says AgMedica operated at approximately 42% of its annual processing capacity during the quarter. Those are management’s descriptions of the business, not a guarantee that unused capacity will turn into sales.
The distinction matters because capacity is only one part of an export operation. A facility can have room to process more material while still needing customers, approvals, shipments and repeat orders. Our reading is that the next test is whether the larger international business becomes durable, rather than whether another theoretical production ceiling can be announced.
Management says future letters will revisit sell-through and reorders, Canadian market share, international revenue and AgMedica utilization. That creates a useful set of measures to compare over time. A later quarter can show whether customer demand repeats and whether domestic changes are producing results; the first letter alone cannot establish either outcome.
Why cannabis exports require more than a buyer
Health Canada’s export guidance provides the regulatory backdrop. Under the Cannabis Regulations, licensed businesses may export cannabis only for medical or scientific purposes. A separate Health Canada permit is required for each shipment. This is not a general export channel for Canadian adult-use products.
The agency considers the destination country’s import permit, treaty obligations, the intended medical or scientific use, and public-health and security questions. That means a commercial supply agreement and permission to ship are distinct steps. An announcement about an overseas customer should not automatically be counted as a completed export or recognized revenue.
For readers following the industry, this helps explain why international opportunity can coexist with uneven quarterly results. The relevant questions extend beyond brand recognition: can the supplier satisfy the importing market’s requirements, deliver consistently and keep the relationship after the first order? National legalization at home does not remove those cross-border conditions.
What to watch in the next report
The clearest follow-up will be the relationship between international growth and Canadian performance. An exporter can report a stronger combined number while one segment contracts. Looking at both prevents a headline about total sales from obscuring the work still needed in the larger domestic business.
It will also be useful to compare cash generation with the pace of expansion. More sales can require more resources before customers pay. A growing revenue line therefore deserves to be considered together with the cash-flow statement and management’s explanation of working capital, rather than in isolation.
Decibel’s quarter shows how differently the same cannabis company can perform across markets. The reported export gains are substantial, and the domestic decline remains part of the result. The next disclosures will help establish whether international momentum persists while the Canadian business improves.
Illustrative cannabis-cultivation stock photograph; not Decibel, AgMedica, their products or their facilities. Photo: Cannafornia / Pexels.